E L Kneepkens1, C L M Krieckaert1, D van der Kleij2, M T Nurmohamed3, I E van der Horst-Bruinsma3, T Rispens4, G J Wolbink5. 1. Department of Rheumatology, Jan van Breemen Research Institute|Reade, Amsterdam, The Netherlands. 2. Laboratory for Monoclonal Therapeutics, Sanquin Diagnostic Services, Amsterdam, The Netherlands. 3. Department of Rheumatology, Jan van Breemen Research Institute|Reade, Amsterdam, The Netherlands Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands. 4. Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands. 5. Department of Rheumatology, Jan van Breemen Research Institute|Reade, Amsterdam, The Netherlands Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Previous data have shown that etanercept levels are associated with clinical response in rheumatoid arthritis. However, for ankylosing spondylitis (AS), data regarding this topic are inconclusive. OBJECTIVES: To investigate the relationship between etanercept levels and clinical response in patients with AS. METHODS: Observational prospective cohort study of 162 patients with AS =treated with etanercept, monitored during 24 weeks of treatment. Etanercept trough levels were determined, retrospectively, using an ELISA. Disease activity was measured using AS Disease Activity Score (ASDAS), including C-reactive protein (CRP) and Bath AS Disease Activity index (BASDAI). Active disease was defined as ASDAS≥2.1. Since etanercept is a drug administered at home there might have been some variation in trough level sampling. RESULTS: At 24 weeks etanercept levels were significantly higher in patients with ASDAS<2.1, (3.8 mg/L; IQR 2.5-5.2) compared with patients with ASDAS≥2.1 (2.3 mg/L; IQR 1.2-3.4; p≤0.001). Generalised estimating equation analysis demonstrated a statistically significant association between etanercept levels and ASDAS, BASDAI, CRP and erythrocyte sedimentation rate (all p<0.001). When patients were categorised into quartiles according to etanercept levels, the lowest quartile (etanercept<1.80 mg/L) comprised 35% of all patients with ASDAS≥2.1 while the highest quartile comprised only 14%. CONCLUSIONS: Disease activity and inflammation are associated with etanercept levels in patients with AS at 24 weeks of treatment. Measuring etanercept levels might help in identifying overtreatment and undertreatment and optimise etanercept therapy in AS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: Previous data have shown that etanercept levels are associated with clinical response in rheumatoid arthritis. However, for ankylosing spondylitis (AS), data regarding this topic are inconclusive. OBJECTIVES: To investigate the relationship between etanercept levels and clinical response in patients with AS. METHODS: Observational prospective cohort study of 162 patients with AS =treated with etanercept, monitored during 24 weeks of treatment. Etanercept trough levels were determined, retrospectively, using an ELISA. Disease activity was measured using AS Disease Activity Score (ASDAS), including C-reactive protein (CRP) and Bath AS Disease Activity index (BASDAI). Active disease was defined as ASDAS≥2.1. Since etanercept is a drug administered at home there might have been some variation in trough level sampling. RESULTS: At 24 weeks etanercept levels were significantly higher in patients with ASDAS<2.1, (3.8 mg/L; IQR 2.5-5.2) compared with patients with ASDAS≥2.1 (2.3 mg/L; IQR 1.2-3.4; p≤0.001). Generalised estimating equation analysis demonstrated a statistically significant association between etanercept levels and ASDAS, BASDAI, CRP and erythrocyte sedimentation rate (all p<0.001). When patients were categorised into quartiles according to etanercept levels, the lowest quartile (etanercept<1.80 mg/L) comprised 35% of all patients with ASDAS≥2.1 while the highest quartile comprised only 14%. CONCLUSIONS: Disease activity and inflammation are associated with etanercept levels in patients with AS at 24 weeks of treatment. Measuring etanercept levels might help in identifying overtreatment and undertreatment and optimise etanercept therapy in AS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Divi Cornec; Brian F Kabat; John R Mills; Melissa Cheu; Amber M Hummel; Darrell R Schroeder; Matthew D Cascino; Paul Brunetta; David L Murray; Melissa R Snyder; Fernando Fervenza; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; E William St Clair; John H Stone; David R Barnidge; Ulrich Specks Journal: Rheumatology (Oxford) Date: 2018-04-01 Impact factor: 7.580
Authors: Meghna Jani; Hector Chinoy; Richard B Warren; Christopher E M Griffiths; Darren Plant; Bo Fu; Ann W Morgan; Anthony G Wilson; John D Isaacs; KimmeL Hyrich; Anne Barton Journal: Arthritis Rheumatol Date: 2015-05 Impact factor: 10.995
Authors: Gaby A M Eliesen; Joris van Drongelen; Hedwig van Hove; Nina I Kooijman; Petra van den Broek; Annick de Vries; Nel Roeleveld; Frans G M Russel; Rick Greupink Journal: Clin Pharmacol Ther Date: 2020-04-08 Impact factor: 6.875
Authors: E H Vogelzang; R C F Hebing; M T Nurmohamed; A W R van Kuijk; J W F Kruijff; M J l'Ami; C L M Krieckaert; G Wolbink Journal: PLoS One Date: 2018-10-09 Impact factor: 3.240
Authors: Johanna Elin Gehin; Guro Løvik Goll; David John Warren; Silje Watterdal Syversen; Joseph Sexton; Eldri Kveine Strand; Tore Kristian Kvien; Nils Bolstad; Elisabeth Lie Journal: Arthritis Res Ther Date: 2019-11-29 Impact factor: 5.156